# PRKCB

Source: https://onco.cc/targets/prkcb/  
OnCo record `prkcb` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRKCB (Protein kinase C beta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.

## Summary

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signalling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'.

CIViC holds 3 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.86, genetic association 0.00, somatic mutation 0.45, clinical 0.92). IntOGen calls it a driver in 4 cohorts (4 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma, Prostate Adenocarcinoma, Stomach Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein kinase C beta; Protein kinase C beta type; PKCβ; PRKCB2; PRKCB1
- Tags: cancer-genes-wave
- Symbol: PRKCB
- Class: kinase
- Biology: Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signalling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signalling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localisation and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Location: Cytoplasm; Nucleus; Membrane (UniProt). Locus 16p12.2-p12.1 (HGNC).
- Where found: Leukaemia: Open Targets association 0.65 with leukaemia (MONDO_0005059); Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076); Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC); Prostate cancer: IntOGen driver in 1 cohort (PRAD); Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD); Systemic mastocytosis: Open Targets association 0.54 with systemic mastocytosis (MONDO_0016586)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94; IntOGen calls it an activating (Act) driver in 4 cohorts; CIViC holds 3 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Adult T-cell Leukaemia/lymphoma.

## Sources

- HGNC HGNC:9395: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9395
- UniProt P05771: https://www.uniprot.org/uniprotkb/P05771/entry
- NCBI Gene 5579: https://www.ncbi.nlm.nih.gov/gene/5579
- Ensembl ENSG00000166501: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166501

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Systemic mastocytosis](https://onco.cc/cancers/systemic-mastocytosis/)

---
JSON: https://onco.cc/api/v1/entities/prkcb.json